Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
CJC-1295 (Modified GRF 1-29)
In plain language
CJC-1295 is a modified analog with DPP-IV resistance. The two forms (with/without DAC) give fundamentally different pharmacological profiles.
For researchers
CJC-1295 is modified Sermorelin (GRF 1-29) with 4 amino acid substitutions that confer resistance to dipeptidyl peptidase IV (DPP-IV). This extends half-life from ~12 minutes (Sermorelin) to ~30 minutes or over 7 days — depending on the form. CJC-1295 without DAC: half-life ~30 minutes, mimics natural pulses. CJC-1295 with DAC (drug affinity complex, lysine at position 30): binds albumin and extends half-life to 6-8 days — creates sustained "bleed" instead of pulses. This is a fundamentally different pharmacological approach and dramatically changes the biological response. In synergy with (Ipamorelin) doubling of pulse amplitude is documented. Storage: -20°C lyophilized; reconstituted — 14 days at 2-8°C.
Scientific literature
Other peptides
Information about CJC-1295 is based on published scientific research and is intended for research purposes. Not medical advice.
Products related to this peptide are for in vitro laboratory research only. Not approved for human consumption.